(Q36661858)

15 August 2017

1 reference

title

Novel therapies for immune tolerance in haemophilia A. (English)

1 reference

15 August 2017

0 references

0 references

Collins PW

1

1 reference

15 August 2017

publication date

1 December 2006

1 reference

15 August 2017

1 reference

15 August 2017

volume

12 Suppl 6

1 reference

15 August 2017

page(s)

94-100; discussion 100-1

1 reference

Induction of immune tolerance in haemophilia A inhibitor patients by the 'Bonn Protocol': predictive parameter for therapy duration and outcome

15 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2006.01372.X

Immune tolerance induction in hemophilia A: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2006.01372.X

Inhibitors in congenital coagulation disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2006.01372.X

Cellular immune responses in hemophilia: why do inhibitors develop in some, but not all hemophiliacs?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2006.01372.X

Acquired haemophilia: review and meta-analysis focused on therapy and prognostic factors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2006.01372.X

Ablation of hemophilic FVIII inhibitors with FVIII priming, cyclophosphamide immune suppression, and rapid tapering of FVIII immune tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2006.01372.X

Rituximab in the treatment of alloimmune factor VIII and IX antibodies in two children with severe haemophilia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2006.01372.X

Rituximab for congenital haemophiliacs with inhibitors: a Canadian experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2006.01372.X

Rituximab in the treatment of high responding inhibitors in severe haemophilia A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2006.01372.X

The use of rituximab in two children with allo-antibodies towards factor VIII.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2006.01372.X

Prospective phase 1/2 study of rituximab in childhood and adolescent chronic immune thrombocytopenic purpura

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2006.01372.X

Rituximab for the treatment of refractory autoimmune hemolytic anemia in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2006.01372.X

Long-term induction of immune tolerance after blockade of CD40-CD40L interaction in a mouse model of hemophilia A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2006.01372.X

Induction of tolerance to factor VIII inhibitors by gene therapy with immunodominant A2 and C2 domains presented by B cells as Ig fusion proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2006.01372.X

Canadian multi-institutional survey of immune tolerance therapy (ITT) -- experience with the use of recombinant factor VIII for ITT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2006.01372.X

Influence of von Willebrand factor on the reactivity of human factor VIII inhibitors with factor VIII.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2006.01372.X

High-dose factor VIII inhibits factor VIII-specific memory B cells in hemophilia A with factor VIII inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2006.01372.X

Successful induction of immune tolerance by continuous infusion of recombinant factor VIII in a haemophilia A patient with high-inhibitor titres

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2006.01372.X

10.1111/J.1365-2516.2006.01372.X

21 January 2018

Identifiers

DOI

1 reference

15 August 2017

1 reference